The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations
Open accessAbstract
More than 2000 mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) have been described that confer a range of molecular cell biological and functional phenotypes. Most of these mutations lead to compromised anion conductance at the apical plasma membrane of secretory epithelia and cause cystic fibrosis (CF) with variable disease severity. Based on the molecular phenotypic complexity of CFTR mutants and their susceptibility to pharmacotherapy, it has been recognized that mutations may impose combinatorial defects in CFTR channel biology. This notion led to the conclusion that the combination of pharmacotherapies addressing single defects (e.g., transcription, translation, folding, and/or gating) may show improved clinical benefit over available low-efficacy monotherapies. Indeed, recent phase 3 clinical trials combining ivacaftor (a gating potentiator) and lumacaftor (a folding corrector) have proven efficacious in CF patients harboring the most common mutation (deletion of residue F508, ΔF508, or Phe508del). This drug combination was recently approved by the U.S. Food and Drug Administration for patients homozygous for ΔF508. Emerging studies of the structural, cell biological, and functional defects caused by rare mutations provide a new framework that reveals a mixture of deficiencies in different CFTR alleles. Establishment of a set of combinatorial categories of the previously defined basic defects in CF alleles will aid the design of even more efficacious therapeutic interventions for CF patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA
Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418 · cited 2×
“…by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), is characterized by a multiorgan pathology affecting the upper and lower airway, gastrointestinal and reproductive tracts, and endocrine system (Riordan et al., 1989; Collins, 1992; Rowe et al., 2005; Cutting, 2015).”
BackgroundMeijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Webb, A. K. (2006) · Cited by 4,369
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Nährlich, L., Mainz, J. G., Adams, C., Engel, C., Herrmann, G., Icheva, V., Lauer, J., Deppisch, C., Wirth, A., Unger, K., et al. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350071 · Cited by 2,525
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O'Riordan, C. R., & Smith, A. E. (1990) · Cell · doi:10.1016/0092-8674(90)90148-8 · Cited by 1,792
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622
Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis
Welsh, M. J., & Smith, A. E. (1993) · Cell · doi:10.1016/0092-8674(93)90353-r · Cited by 1,485
Rowe, S. M., Miller, S., & Sorscher, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043184 · Cited by 1,398
Self-citationRescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,228
Self-citationPTC124 targets genetic disorders caused by nonsense mutations
Welch, E. M., Barton, E. R., Zhuo, J., Tomizawa, Y., Friesen, W. J., Trifillis, P., Paushkin, S., Patel, M., Trotta, C. R., Hwang, S., et al. (2007) · Nature · doi:10.1038/nature05756 · Cited by 1,137
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088
Self-citationCystic fibrosis genetics: from molecular understanding to clinical application
Cutting, G. R. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3849 · Cited by 965
Self-citationRatjen, F., & Döring, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12567-6 · Cited by 885
Cystic fibrosis: molecular biology and therapeutic implications
Collins, F. (1992) · Science · doi:10.1126/science.1375392 · Cited by 822
Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung
Pezzulo, A. A., Tang, X. X., Hoegger, M. J., Abou Alaiwa, M. H., Ramachandran, S., Moninger, T. O., Karp, P. H., Wohlford-Lenane, C. L., Haagsman, H. P., van Eijk, M., et al. (2012) · Nature · doi:10.1038/nature11130 · Cited by 808
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation
Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M. P., Dunitz, J. M., Durie, P. R., Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909825 · Cited by 807
Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation
Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Jallat, S., Dott, K., Dreyer, D., Crystal, R. G., Pavirani, A., Lecocq, J.-P., et al. (1991) · Nature · doi:10.1038/354526a0 · Cited by 707
Origins of Cystic Fibrosis Lung Disease
Stoltz, D. A., Meyerholz, D. K., & Welsh, M. J. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300109 · Cited by 669
CYSTIC FIBROSIS: GENOTYPIC AND PHENOTYPIC VARIATIONS
Zielenski, J., & Tsui, L.-C. (1995) · Annual Review of Genetics · doi:10.1146/annurev.ge.29.120195.004021 · Cited by 631
Sosnay, P. R., Siklosi, K. R., Van Goor, F., Kaniecki, K., Yu, H., Sharma, N., Ramalho, A. S., Amaral, M. D., Dorfman, R., Zielenski, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2745 · Cited by 630
Self-citationClancy, J. P., Rowe, S. M., Accurso, F. J., Aitken, M. L., Amin, R. S., Ashlock, M. A., Ballmann, M., Boyle, M. P., Bronsveld, I., Campbell, P. W., et al. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-200393 · Cited by 515
Airway Surface Dehydration in Cystic Fibrosis: Pathogenesis and Therapy
Boucher, R. C. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.071905.105316 · Cited by 512
Genotype and Phenotype in Cystic Fibrosis
Zielenski, J. (2000) · Respiration · doi:10.1159/000029497 · Cited by 482
Mutations in CFTR associated with mild-disease-form CI- channels with altered pore properties
Sheppard, D. N., Rich, D. P., Ostedgaard, L. S., Gregory, R. J., Smith, A. E., & Welsh, M. J. (1993) · Nature · doi:10.1038/362160a0 · Cited by 467
Self-citationBoyle, M. P., Bell, S. C., Konstan, M. W., McColley, S. A., Rowe, S. M., Rietschel, E., Huang, X., Waltz, D., Patel, N. R., & Rodman, D. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70132-8 · Cited by 452
The Cystic Fibrosis Transmembrane Conductance Regulator
Riordan, J. R. (1993) · Annual Review of Physiology · doi:10.1146/annurev.ph.55.030193.003141 · Cited by 446
Highsmith, W. E., Burch, L. H., Zhou, Z., Olsen, J. C., Boat, T. E., Spock, A., Gorvoy, J. D., Quittell, L., Friedman, K. J., Silverman, L. M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410133311503 · Cited by 441
Ivacaftor potentiation of multiple CFTR channels with gating mutations
Yu, H., Burton, B., Huang, C.-J., Worley, J., Cao, D., Johnson, J. P., Urrutia, A., Joubran, J., Seepersaud, S., Sussky, K., et al. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2011.12.005 · Cited by 423
Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane
Okiyoneda, T., Barrière, H., Bagdány, M., Rabeh, W. M., Du, K., Höhfeld, J., Young, J. C., & Lukacs, G. L. (2010) · Science · doi:10.1126/science.1191542 · Cited by 408 · cited 2×
“, 2010), 2) preventing post-Golgi ubiquitination (Fu et al., 2015; Okiyoneda et al., 2010), 3) restor-”
BackgroundThe prevalence of cystic fibrosis in the European Union
Farrell, P. M. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.03.007 · Cited by 399
Lukacs, G. L., Mohamed, A., Kartner, N., Chang, X. B., Riordan, J. R., & Grinstein, S. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06954.x · Cited by 396
Self-citationLukacs, G. L., Chang, X. B., Bear, C., Kartner, N., Mohamed, A., Riordan, J. R., & Grinstein, S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80582-1 · Cited by 387
Self-citationMechanism-based corrector combination restores ΔF508-CFTR folding and function
Okiyoneda, T., Veit, G., Dekkers, J. F., Bagdany, M., Soya, N., Xu, H., Roldan, A., Verkman, A. S., Kurth, M., Simon, A., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1253 · Cited by 378 · cited 11×
“For example, while nearly complete processing correction of P67L- and R170G-CFTR (class II) was achieved with VX-809 treatment (Okiyoneda et al., 2013; Ren et al., 2013; Veit et al., 2014), VX-809 only partially reversed the folding defect of some other class II mutants; for example, N1303K and ΔF508 (Okiyoneda et al.…”
BackgroundInfluentialSelf-citationDu, K., Sharma, M., & Lukacs, G. L. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb882 · Cited by 356
SCHECHTER, M. S., SHELTON, B. J., MARGOLIS, P. A., & FITZSIMMONS, S. C. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.6.9912100 · Cited by 347
Kerem, E., Konstan, M. W., De Boeck, K., Accurso, F. J., Sermet-Gaudelus, I., Wilschanski, M., Elborn, J. S., Melotti, P., Bronsveld, I., Fajac, I., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70100-6 · Cited by 346
Van Goor, F., Yu, H., Burton, B., & Hoffman, B. J. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2013.06.008 · Cited by 337
Linde, L., Boelz, S., Nissim-Rafinia, M., Oren, Y. S., Wilschanski, M., Yaacov, Y., Virgilis, D., Neu-Yilik, G., Kulozik, A. E., Kerem, E., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28523 · Cited by 300
Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression
Veit, G., Avramescu, R. G., Perdomo, D., Phuan, P.-W., Bagdany, M., Apaja, P. M., Borot, F., Szollosi, D., Wu, Y.-S., Finkbeiner, W. E., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008889 · Cited by 287 · cited 6×
“For example, while nearly complete processing correction of P67L- and R170G-CFTR (class II) was achieved with VX-809 treatment (Okiyoneda et al., 2013; Ren et al., 2013; Veit et al., 2014), VX-809 only partially reversed the folding defect of some other class II mutants; for example, N1303K and ΔF508 (Okiyoneda et al.”
BackgroundInfluentialSelf-citationRen, H. Y., Grove, D. E., De La Rosa, O., Houck, S. A., Sopha, P., Van Goor, F., Hoffman, B. J., & Cyr, D. M. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-05-0240 · Cited by 284
Self-citationRabeh, W. M., Bossard, F., Xu, H., Okiyoneda, T., Bagdany, M., Mulvihill, C. M., Du, K., di Bernardo, S., Liu, Y., Konermann, L., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.024 · Cited by 280 · cited 2×
“According to one hypothesis, robust folding correction of ΔF508-CFTR requires corrector combinations to avert its NBD1-MSD1/2 interface and NBD1 stability defects (Mendoza et al., 2012; Rabeh et al., 2012; He et al., 2013; Okiyoneda et al., 2013).”
BackgroundModifier genes in Mendelian disorders: the example of cystic fibrosis
Cutting, G. R. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05879.x · Cited by 271 · cited 2×
“, 2013), which is further influenced by modifier genes (Collaco and Cutting, 2008; Cutting, 2010) and by the environmental and socioeconomic status of patients (Schechter et al.”
BackgroundSelf-citationRequirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences
Mendoza, J. L., Schmidt, A., Li, Q., Nuvaga, E., Barrett, T., Bridges, R. J., Feranchak, A. P., Brautigam, C. A., & Thomas, P. J. (2012) · Cell · doi:10.1016/j.cell.2011.11.023 · Cited by 261
Tarran, R., Grubb, B. R., Parsons, D., Picher, M., Hirsh, A. J., Davis, C. W., & Boucher, R. C. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00286-6 · Cited by 259
Du, M., Liu, X., Welch, E. M., Hirawat, S., Peltz, S. W., & Bedwell, D. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711795105 · Cited by 256
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis
Hutt, D. M., Herman, D., Rodrigues, A. P. C., Noel, S., Pilewski, J. M., Matteson, J., Hoch, B., Kellner, W., Kelly, J. W., Schmidt, A., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.275 · Cited by 252
Self-citationSermet-Gaudelus, I., Boeck, K. D., Casimir, G. J., Vermeulen, F., Leal, T., Mogenet, A., Roussel, D., Fritsch, J., Hanssens, L., Hirawat, S., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0137oc · Cited by 248
Chen, J.-H., Stoltz, D. A., Karp, P. H., Ernst, S. E., Pezzulo, A. A., Moninger, T. O., Rector, M. V., Reznikov, L. R., Launspach, J. L., Chaloner, K., et al. (2010) · Cell · doi:10.1016/j.cell.2010.11.029 · Cited by 240
Moss, R. B., Flume, P. A., Elborn, J. S., Cooke, J., Rowe, S. M., McColley, S. A., Rubenstein, R. C., & Higgins, M. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00201-5 · Cited by 228
Haardt, M., Benharouga, M., Lechardeur, D., Kartner, N., & Lukacs, G. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21873 · Cited by 218
Self-citationChronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis
Wilschanski, M., Miller, L. L., Shoseyov, D., Blau, H., Rivlin, J., Aviram, M., Cohen, M., Armoni, S., Yaakov, Y., Pugatch, T., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00120910 · Cited by 205
Nanomolar Affinity Small Molecule Correctors of Defective ΔF508-CFTR Chloride Channel Gating
Yang, H., Shelat, A. A., Guy, R. K., Gopinath, V. S., Ma, T., Du, K., Lukacs, G. L., Taddei, A., Folli, C., Pedemonte, N., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303098200 · Cited by 202
Self-citationStructure and association of ATP-binding cassette transporter nucleotide-binding domains
Kerr, I. D. (2002) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0304-4157(01)00008-9 · Cited by 174
Farinha, C. M., King-Underwood, J., Sousa, M., Correia, A. R., Henriques, B. J., Roxo-Rosa, M., Da Paula, A. C., Williams, J., Hirst, S., Gomes, C. M., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.06.004 · Cited by 163
Xue, X., Mutyam, V., Tang, L., Biswas, S., Du, M., Jackson, L. A., Dai, Y., Белахов, В. В., Shalev, M., Chen, F., et al. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0282oc · Cited by 161
Self-citationBompadre, S. G., Sohma, Y., Li, M., & Hwang, T. (2007) · The Journal of General Physiology · doi:10.1085/jgp.200609667 · Cited by 159
He, L., Kota, P. B., Aleksandrov, A. A., Cui, L., Jensen, T., Dokholyan, N. V., & Riordan, J. R. (2012) · The FASEB Journal · doi:10.1096/fj.12-216119 · Cited by 155
Cooperative Assembly and Misfolding of CFTR Domains In Vivo
Du, K., & Lukacs, G. L. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-09-0950 · Cited by 147 · cited 1×
“The prototypical class II mutation, ΔF508-CFTR (Phe508del), elicits a complex folding defect that compromises both NBD1 stability and the channel’s cooperative domain assembly (Du and Lukacs, 2009; Du et al., 2005; Mendoza et al., 2012; Rabeh et al., 2012).”
BackgroundMechanisms of CFTR Folding at the Endoplasmic Reticulum
Kim, S. J., & Skach, W. R. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00201 · Cited by 142
Self-citationInfluence of cell background on pharmacological rescue of mutant CFTR
Pedemonte, N., Tomati, V., Sondo, E., & Galietta, L. J. V. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00404.2009 · Cited by 136
Update on gene modifiers in cystic fibrosis
Collaco, J. M., & Cutting, G. R. (2008) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283121cdc · Cited by 127
Self-citationCorrector VX-809 stabilizes the first transmembrane domain of CFTR
Loo, T. W., Bartlett, M. C., & Clarke, D. M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.028 · Cited by 118
Luciani, A., Villella, V. R., Esposito, S., Gavina, M., Russo, I., Silano, M., Guido, S., Pettoello‐Mantovani, M., Carnuccio, R., Scholte, B. J., et al. (2012) · Autophagy · doi:10.4161/auto.21483 · Cited by 113
Barr, H. L., Britton, J. R., Smyth, A. R., & Fogarty, A. (2011) · BMJ · doi:10.1136/bmj.d4662 · Cited by 99
Highsmith, W. E., Burch, L. H., Zhou, Z., Olsen, J. C., Strong, T. V., Smith, T., Friedman, K. J., Silverman, L. M., Boucher, R. C., Collins, F. S., et al. (1997) · Human Mutation · Cited by 92
Derichs, N., Jin, B., Song, Y., Finkbeiner, W. E., & Verkman, A. S. (2011) · The FASEB Journal · doi:10.1096/fj.10-179549 · Cited by 84
Awatade, N. T., Uliyakina, I., Farinha, C. M., Clarke, L. A., Mendes, K., Solé, A., Pastor, J., Ramos, M. M. P., & Amaral, M. D. (2014) · EBioMedicine · doi:10.1016/j.ebiom.2014.12.005 · Cited by 77
Goor, F. V., Yu, H. D., Burton, B., Huang, C.-J., Hoffman, B. J., Cao, H., Machuca, T., Yeung, J. C., Bonato, R., Duan, C., et al. (2012) · Cited by 76
CFTR Modulators for the Treatment of Cystic Fibrosis.
Pettit, R. S., & Fellner, C. (2014) · PubMed · Cited by 73
A Stabilizing Influence: CAL PDZ Inhibition Extends the Half‐Life of ΔF508‐CFTR
Cushing, P. R., Vouillème, L., Pellegrini, M., Boisguérin, P., & Madden, D. R. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201005585 · Cited by 69
Silvis, M. R., Picciano, J. A., Bertrand, C. A., Weixel, K. M., Bridges, R. J., & Bradbury, N. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212843200 · Cited by 58
Char, J. E., Wolfe, M. H., Cho, H., Park, I., Jeong, J. H., Frisbee, E., Dunn, C. E., Davies, Z. A., Milla, C. E., Moss, R. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088564 · Cited by 58
Rapino, D., Sabirzhanova, I. B., Lopes‐Pacheco, M., Grover, R., Guggino, W. B., & Cebotaru, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119796 · Cited by 53
Self-citationCurcumin and genistein additively potentiate G551D-CFTR
Yu, Y.-C., Miki, H., Nakamura, Y., Hanyuda, A., Matsuzaki, Y., Abe, Y., Yasui, M., Tanaka, K., Hwang, T., Bompadre, S. G., et al. (2011) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2011.03.001 · Cited by 53
Cyr, D. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb0105-2 · Cited by 37
Self-citationDetrimental effects of secondhand smoke exposure on infants with cystic fibrosis
Kopp, B. T., Sarzynski, L., Khalfoun, S., Hayes, D., Thompson, R., Nicholson, L., Long, F. R., Castile, R. G., & Groner, J. A. (2014) · Pediatric Pulmonology · doi:10.1002/ppul.23016 · Cited by 36
Fu, L., Rab, A., Tang, L. P., Bebők, Z., Rowe, S. M., Bartoszewski, R., & Collawn, J. F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123131 · Cited by 36
Visca, A., Bishop, C. T., Hilton, S. C., & Hudson, V. M. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.03.006 · Cited by 36
Gentzsch, M., Aleksandrov, A. A., Aleksandrov, L. A., & Riordan, J. R. (2002) · Biochemical Journal · doi:10.1042/bj20020511 · Cited by 29
Wang, Y., Liu, J., Loizidou, A., Bugeja, L., Warner, R., Hawley, B. R., Cai, Z., Toye, A. M., Sheppard, D. N., & Li, H. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12791 · Cited by 27
Self-citationTaylor-Robinson, D. C., Thielen, K., Pressler, T., Olesen, H. V., Diderichsen, F., Diggle, P. J., Smyth, R. L., & Whitehead, M. M. (2014) · European Respiratory Journal · doi:10.1183/09031936.00063714 · Cited by 25
Fanen, P., Labarthe, R., Garnier, F., Benharouga, M., Goossens, M., & Edelman, A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.48.30563 · Cited by 24
Yousef, S., Solomon, G. M., Brody, A. S., Rowe, S. M., & Colin, A. A. (2015) · CHEST Journal · doi:10.1378/chest.14-1198 · Cited by 19
Increased folding and channel activity of a rare cystic fibrosis mutant with CFTR modulators
Caldwell, R. A., Grove, D. E., Houck, S. A., & Cyr, D. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00044.2011 · Cited by 17
Self-citation
Cited by
In vivo aspects of protein folding and quality control
Balchin, D., Hayer-Hartl, M., & Hartl, F. U. (2016) · Science · doi:10.1126/science.aac4354 · Cited by 1,439
Shteinberg, M., Haq, I. J., Polineni, D., & Davies, J. C. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32542-3 · Cited by 682
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Lopes-Pacheco, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01662 · Cited by 535
Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases
Cornec-Le Gall, E., Torres, V. E., & Harris, P. C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017050483 · Cited by 406
Cystic fibrosis in the year 2020: A disease with a new face
De Boeck, K. (2020) · Acta Paediatrica · doi:10.1111/apa.15155 · Cited by 332
Metadata
- Authors
- Veit, G., Avramescu, R. G., Chiang, A. N., Houck, S. A., Cai, Z., Peters, K. W., Hong, J. S., Pollard, H. B., Guggino, W. B., Balch, W. E., Skach, W. R., Cutting, G. R., Frizzell, R. A., Sheppard, D. N., Cyr, D. M., Sorscher, E. J., Brodsky, J. L., & Lukacs, G. L.
- Venue
- Molecular Biology of the Cell
- Published
- 2016-02
- Volume
- 27
- Issue
- 3
- Pages
- 424-433
- ISSN
- 1059-1524 (ISSN-L)
- 1939-4586
- OpenAlex
- W2337762305
- Cited by
- 580
- References
- 86
- FWCI
- 41.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.